Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

Situationships come and go, but dried flowers last forever.

H.C. Wainwright analyst Pat Trucchio adjusted the price target for Cybin Inc. (NYSE:CYBN) stock, lowering it to $150.00 from the previous $190.00 while maintaining a Buy rating on the company.

Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

Politics is stressing Americans out—77% say the nation’s future is their top concern, per a 2024 APA survey on national ...

Lexapro is an antidepressant medication commonly prescribed for anxiety. Here's how to know the best time of day to take it.

One of the most effective methods is therapy, particularly cognitive-behavioral therapy (CBT). CBT helps individuals identify and change negative thought patterns that contribute to anxiety.

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Cybin (CYBN) to $73 from $86 and keeps a Buy rating on the shares. The ...

Political anxiety has become a dominant theme in our culture. We present some of the prominent features and suggestions about ...